Preferred attributes of the new fast dissolving tablet (FDT) formulation of ebastine in patients with allergy

Journal of Outcomes Research

Volumn 10, Issue 13-22, 2006, Pages 13-22

  Roger, Albert ^a   Fortea, J ^b   Artes M ^c   Montilla, L ^c  

^a Centre Roger Barri d Asmologia i Al lèrgia   (Spain)

^b Almirall Prodesfarma S A   (Spain)

^c Adelphi Targis   (Spain)

Author keywords

Allergy; Attributes; Ebastine; Fast dissolving tablet (FDT); Preference

Indexed keywords

ANTIHISTAMINIC AGENT; EBASTINE; PLACEBO;

ADULT; ALLERGIC RHINITIS; ALLERGIC URTICARIA; ARTICLE; CONTROLLED STUDY; DISSOLUTION; DRUG SOLUBILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTERVIEW; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; SCORING SYSTEM; SKIN ALLERGY; TABLET FORMULATION;

EID: 33745759814     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ratner P, Falqués M, Chuecos F et al. Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. International Archives of Allergy and Immunology 2005; 138: 312-318.
2. Hampel F Jr, Howland W 3rd, Van Bavel J et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. Journal of Investigational Allergology & Clinical Immunology 2004; 14: 56-63.
3. Hurst M, Spencer CM. Ebastine - an update of its use in allergic disorders. Drugs 2000; 59: 981-1006.
4. Bousquet J, Gaudano EM, Palma Carlos AG et al. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy 1999; 54: 562-568.
5. Davies RJ. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clinical Drug Investigation 1998; 16: 413-420.
6. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996; 52: 20-25.
7. Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Annals of Allergy, Asthma & Immunology 1996; 76: 507-512.
8. PSUR. 18th Periodic Safety Update Report of Ebastine. February 2006.
9. Salva M, Carreno B, Pintos M et al. Phase I, single dose, open-label, randomized, crossover bioequivalence studies of ebastine 10 and 20 mg fast-dissolving tablets in healthy male volunteers. In: European Academy of Allergology and Clinical Immunology (EAACI); Bilbao; 2004. Poster OC9.
10. Haynes RB, Montague P, Oliver T et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database of Systematic Reviews 2000; 2: CD000011.
11. Gil VF, Belda J, Piñero F et al. El incumplimiento en la práctica clínica: toma de decisiones diagnósticas y terapéuticas. Medicina Clínica 2001; 116: 77-86.
12. Dowson AJ, Charlesworth BR. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. International Journal of Clinical Practice 2003; 57: 573-576.
13. Brampton WJ, Plantevin OM. Double-blind crossover study of the efficacy and acceptability of oxazepam Expidet® tablets compared to placebo in patients undergoing gynaecological surgery. Journal of International Medical Research 1985; 13: 169-173.
14. Datamonitor. Strategic Perspectives: Allergic Rhinitis - impact of a blockbuster going bust. DMHC1794, published August 2002. Available at: www.datamonitor.com/healthcare [accessed 2 May 2006].
15. Lang DM. Management of allergic rhinitis. Geriatric Times March/April 2002, Vol. III, issue 2.
16. Channer KS, Virjee JP. The effect of formulation on oesophageal transit. Journal of Pharmacy and Pharmacology 1985; 37: 126-129.
17. Channer KS, Virjee JP. Effect of size and shape of tablets on their oesophageal transit. Journal of Clinical Pharmacology 1986; 26: 141-146.
18. Fell JT. Esophageal transit of tablets and capsules. American Journal of Hospital Pharmacy 1983; 40: 946-948.
19. D'Arcy PF. Oesophageal problems with tablets and capsules. Pharmacology International 1984; 5: 109.
20. Ergun GA, Miskovitz PF. Aging and the esophagus: common pathologic conditions and their effect upon swallowing in the geriatric population. Dysphagia 1992; 7: 58-63.
21. Koch WM. Swallowing disorders: diagnosis and therapy. Medical Clinics of North America 1993; 77: 571-582.
22. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. Journal of Pharmacy and Pharmacology 1998; 50: 375-382.
23. Virley P, Yarwood R. Zydis - a novel, fast-dissolving dosage form. Manufacturing Chemist 1990; 61: 36-37.
24. Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Critical Reviews in Therapeutic Drug Carrier Systems 2000; 17: 61-72.
25. Fox DA. Rapid-dissolving dosage forms: an expanding therapeutic approach. Paper presented at the 1996 Drug Delivery Systems Workshop at the Institute of International Research.
26. Slowson M, Slowson, S. What to do when patients cannot swallow their medications. Pharmacy Times 1985; 51: 90-96.
27. Doheny K. You really expect me to swallow those horse pills? American Druggist 1993; 208: 34-35.
28. Juniper EF. The impact of patient compliance on effective asthma management. Current Opinion in Pulmonary Medicine 2003; 9 (Suppl. 1): S8-S10.
29. Diamond R. Drugs and the quality of life: the patient's point of view. Journal of Clinical Psychiatry 1985, 46: 29-35.